CRHR2 and myalgic encephalomeyelitis/chronic fatigue syndrome: That is, where healthy subjects reversed the effects of high-dose CT38s administration, ME/CFS patients did not, suggesting an impaired ability to reverse the effects of intense CRFR2 stimulation and therefore a susceptibility to CRFR2 maladaptation.